LIB-01: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข4 clinical studies cited
- โขOverall evidence level: moderate
- โข7 research gaps identified
Research Studies
Libiguins A and B: Novel Phragmalin Limonoids Isolated from Neobeguea mahafalensis Causing Profound Enhancement of Sexual Activity
Kossouoh C, Moutard C, Rasoanaivo P, Wikberg JES, et al. (2014) โข Planta Medica
Ethnopharmacological study identifying two novel phragmalin limonoids (libiguins A and B) from Neobeguea mahafalensis root bark. These compounds produced profound and long-lasting enhancement of sexual activity in male rodents at extremely low doses.
Key Findings
- Novel 1,8,9-orthoacetate phragmalin limonoids with C-16/30 delta-lactone ring identified
- Treatment at 0.004-0.4 mg/kg/day for 3 days produced sustained effects lasting up to 11 days
- Augmentation of frequency and sustainment of mounting behavior in male rodents
- First report of limonoids with pro-erectile activity
Limitations: Preclinical rodent study only; small molecule isolation and characterization without human pharmacological data; limited dose-response characterization
Prolonged Pro-Erectile Facilitator Effect of LIB-01 in Anesthetized Wistar Rats
Dicot Pharma Research Team (2022) โข Journal of Sexual Medicine
Preclinical study demonstrating the prolonged pro-erectile effect of LIB-01 in anesthetized Wistar rats, supporting the unique pharmacodynamic profile observed with libiguins.
Key Findings
- Confirmed prolonged pro-erectile facilitator effect of LIB-01 in rat model
- Effect duration extended well beyond plasma drug exposure
- Supports mechanism of action involving pathway modulation rather than direct receptor occupancy
Limitations: Animal model; anesthetized preparations may not fully recapitulate physiological erectile mechanisms
Results of a First-in-Human Trial of LIB-01, a Novel, First in Class Potential Oral ED Drug with Unique Pharmacodynamic Properties
Dicot Pharma investigators (2024) โข Journal of Sexual Medicine
Phase 1 first-in-human study evaluating safety, tolerability, pharmacokinetics, and pro-erectile effects of LIB-01 at single and multiple ascending doses (10-150 mg) in healthy male volunteers.
Key Findings
- Safe and well tolerated at all dose levels (10-150 mg single and multiple doses)
- Erectile function improvements demonstrated by IIEF-EF and RigiScan measures
- Unique pharmacodynamic profile with onset within 7 days of 3-day dosing course
- Duration of action of at least 28 days post-treatment
- Most common adverse effects were GI-related (nausea, vomiting, diarrhea) occurring within 24 hours
Limitations: Healthy volunteer population (not ED patients); conference abstract only without full publication; industry-funded study with authors as consultants, employees, or shareholders
Phase 2a Trial Results: LIB-01 Improves Erectile Function with Sustained Effect
Dicot Pharma investigators (2025) โข Conference presentation (October 2025)
Phase 2a double-blind, placebo-controlled trial of LIB-01 (25 mg and 50 mg) in 156 men with mild to moderate ED across 6 sites in Sweden, Denmark, and the Netherlands.
Key Findings
- 50 mg group showed 8.5-point IIEF-EF improvement from baseline (p=0.008 vs baseline)
- 31% complete responders (IIEF-EF >25) vs 0% placebo (p=0.04)
- Effect sustained through the entire 8-week observation period
- Placebo effect tapered off while LIB-01 effect was maintained
- Well tolerated at all dose levels
Limitations: Relatively small sample size (n=156); 8-week observation period; mild to moderate ED only (severe ED excluded); conference presentation without full peer-reviewed publication; p=0.11 vs placebo for primary endpoint in 50 mg group
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
0View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขFull peer-reviewed publications of Phase 1 and Phase 2a data (currently available only as conference abstracts and press releases)
- โขMechanism of action clarification: precise molecular pathway by which short-term LIB-01 exposure produces month-long pharmacodynamic effects
- โขDose-response characterization in larger patient populations and across ED severity ranges including severe ED
- โขLong-term safety and efficacy data with repeated dosing courses
- โขComparison with PDE5 inhibitors and bremelanotide in head-to-head trials
- โขEvaluation in female sexual dysfunction populations
- โขInvestigation of potential metabolic effects (obesity, diabetes) identified in preclinical studies
Research Overview#
LIB-01's research history spans from ethnopharmacological discovery in Madagascar to Phase 2 clinical trials in Europe. The development trajectory is notable for being rooted in traditional medicine: researchers investigating Madagascan plants used to treat sexual dysfunction in older men identified the unprecedented pro-erectile activity of libiguins, leading to the pharmaceutical development of LIB-01 as a synthetic analog.
The evidence base is currently limited to preclinical studies, a Phase 1 first-in-human trial, and a Phase 2a efficacy study. While results are consistently positive, most clinical data are available only as conference abstracts and press releases rather than full peer-reviewed publications. The evidence level is classified as moderate, reflecting the early development stage and limited independent verification.
Preclinical Discovery#
Ethnopharmacological Origins#
The discovery of LIB-01's parent compounds originated from a collaboration between Professor Jarl Wikberg (Uppsala University, Sweden) and Dr. Philippe Rasoanaivo (Madagascar) investigating traditional medicines used for sexual dysfunction. A root bark decoction from Neobeguea mahafalensis, a tree endemic to southwestern Madagascar, displayed extraordinary potency in enhancing sexual activity in rodent models.
Libiguin Isolation and Characterization (PMID 24549927)#
Chemical investigation of the root bark identified two novel compounds named libiguins A and B. These were characterized as 1,8,9-orthoacetate phragmalin limonoids with a unique C-16/30 delta-lactone ring, representing the first known limonoids with pro-erectile activity.
The preclinical findings were remarkable:
- Treatment with libiguins at doses as low as 0.004 mg/kg/day for just 3 consecutive days produced sustained enhancement of sexual mounting behavior
- Effects persisted for up to 11 days after the last dose
- The potency was exceptionally high compared to other known pro-erectile natural products
Nonclinical Safety and Pharmacology#
Dicot Pharma conducted a comprehensive nonclinical program including toxicology, safety pharmacology, and pharmacodynamic studies. Presentations at the Journal of Sexual Medicine (2024) described the nonclinical package supporting clinical development, including the prolonged pro-erectile effect in Wistar rats that confirmed the unique pharmacodynamic profile.
Phase 1 First-in-Human Trial (2023-2024)#
The Phase 1 study was a randomized, double-blind, placebo-controlled trial evaluating LIB-01 in healthy male volunteers. Results were presented at the International Society for Sexual Medicine annual meeting and published as a conference abstract in the Journal of Sexual Medicine (2024).
Study Design#
- Single ascending dose (SAD) and multiple ascending dose (MAD) cohorts
- Dose range: 10 mg to 150 mg
- MAD cohort: 3 consecutive days of once-daily oral dosing
- Monitoring included IIEF-EF questionnaire and RigiScan nocturnal penile rigidity
Key Findings#
- Safe and well tolerated across all dose levels
- Erectile function improvements demonstrated by both subjective (IIEF-EF) and objective (RigiScan) measures
- Onset of pro-erectile effect within 7 days of the 3-day dosing course
- Duration of action of at least 28 days after the last dose
- Most common adverse effects were gastrointestinal (nausea, vomiting, diarrhea), occurring within 24 hours of dosing
The combination of short plasma half-life and prolonged pharmacodynamic effect was described as "unique" and "entirely unprecedented" in the ED therapeutic field.
Phase 2a Trial (2024-2025)#
The Phase 2a study was the first trial in ED patients, designed to evaluate efficacy and confirm the unique pharmacodynamic profile in the target population.
Study Design#
- Double-blind, placebo-controlled, multi-center trial
- 6 clinical sites in Sweden, Denmark, and the Netherlands
- 156 men aged 26-65 with mild to moderate ED
- Three arms: LIB-01 25 mg, LIB-01 50 mg, placebo
- 3-day oral dosing with follow-up at weeks 4 and 8
Efficacy Results#
50 mg group:
- IIEF-EF improvement of 8.5 points from baseline (p=0.008 vs baseline, p=0.11 vs placebo)
- The 8.5-point improvement exceeded the minimum clinically important difference (MCID) of 5 points for this severity group
- 31% of patients were complete responders (IIEF-EF >25, indicating normal erectile function) vs 0% in placebo (p=0.04 vs placebo)
- The pro-erectile effect was maximal during the first 4 weeks and sustained through the full 8-week observation period
- The placebo effect tapered off over time while the LIB-01 effect was maintained
Safety#
Treatment with LIB-01 was well tolerated at all dose levels. Detailed adverse event data from the Phase 2a study have not been fully published.
Evidence Quality Assessment#
| Criterion | Assessment | Details |
|---|---|---|
| Study design | Phase 1/2a RCTs | Double-blind, placebo-controlled |
| Sample size | Small (Phase 2a n=156) | Early clinical development |
| Consistency | Good | Consistent results across preclinical and clinical |
| Publication status | Limited | Mostly conference abstracts and press releases |
| Independent replication | None | Single sponsor, no independent studies |
| Regulatory pathway | Active IND | Proceeding to Phase 2b (planned 2026) |
| Mechanism clarity | Partial | MC4R modulation proposed but not fully elucidated |
Next Steps#
Dicot Pharma has announced plans to initiate a Phase 2b study in 2026, which will further evaluate dose optimization and efficacy in a larger ED patient population. The company is also developing manufacturing scale-up processes and exploring potential applications in premature ejaculation and metabolic diseases.
Related Reading#
Frequently Asked Questions About LIB-01
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.